PTPI
Petros Pharmaceuticals, Inc.0.0120
-0.0010-7.69%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
508.47KP/E (TTM)
-Basic EPS (TTM)
-29.01Dividend Yield
0%Recent Filings
8-K
RSU grants to executives
Petros Pharmaceuticals granted 7,250,000 RSUs on January 2, 2026, to Chairman Joshua Silverman (4,375,000), director Bruce Bernstein (1,875,000), President Fady Boctor (500,000), and director Wayne Walker (500,000). Half vested immediately; the rest vests in six months if service continues. Issued outside the 2020 plan. Aligns key leaders' interests with shareholders.
10-Q
Q3 FY2025 results
Petros Pharmaceuticals posted a Q3 operating loss of $0.99M, 17% narrower y/y, while nine-month continuing ops loss narrowed to $4.2M from $0.2M amid discontinued assets. Cash swelled to $6.1M on $8.5M net equity raise, funding $3.8M ops burn; no debt disclosed. SG&A ticked up 5% y/y nine-month but fell sharply q/q on lower fees and taxes. Warrant gains offset issuance costs. Equity turned positive at $3.4M. Cash lasts months, not a year. Nasdaq delisting crimps liquidity.
8-K
Nasdaq delisting notice issued
Nasdaq notified Petros Pharmaceuticals on November 3, 2025, of its intent to delist the company's common stock effective ten days after filing Form 25, following suspension on May 22 and OTC transfer July 1. Shares continue trading uninterrupted on OTCID Basic Market under PTPI. Reporting obligations persist under Exchange Act Sections 13 and 15(d). Delisting finalizes Nasdaq exit.
8-K
Auditor change announced
Petros Pharmaceuticals dismissed CBIZ CPAs as its independent auditor on August 29, 2025, after a brief engagement starting April 5, and immediately appointed HTL International. No disagreements arose, but a material weakness in internal controls persists from prior disclosures. This switch ensures audit continuity for the fiscal year. Oversight gaps linger.
10-Q
Q2 FY2025 results
Petros Pharmaceuticals posted a $3.3M operating loss from continuing operations for Q2 FY2025 ended June 30, 2025, up 33% y/y from $1.3M amid higher professional fees and stock-based comp, while net income swung to $5.4M thanks to a $7.0M gain on subsidiary assignment and Vivus settlement. Cash burn from continuing ops hit $2.7M over six months, offset by $8.5M net from February's equity raise, leaving $7.3M in cash and $4.4M working capital—yet liquidity falls short for 12 months, flagging going concern doubts. Warrant liability gains of $10.3M (six months) masked deemed dividends slashing EPS to $(1.29) basic/diluted on 25.9M shares, with anti-dilution effects diluting common holders. Delisting to OTC in May curbs liquidity. Nasdaq woes persist.
IPO
Website
Employees
Sector
Industry
CPMD
Cannapharmarx Inc.
0.00-0.00
CRON
Cronos Group Inc. Common Share
3.16+0.11
HSTI
High Sierra Technologies Inc.
1.40+0.00
PETS
PetMed Express, Inc.
3.90+1.03
PETV
PetVivo Holdings Inc.
1.16-0.03
PLSH
Panacea Life Sciences Holdings,
0.09+0.00
PNXP
Pineapple Express Cannabis Comp
0.01+0.00
PRFX
PainReform Ltd.
0.98+0.09
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18